Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402870 | 0.81 | CDK1 (0.66) | CDK1ADORA2AADORA1YTHDC1CCNB1 | |
| SCHEMBL790146 | 0.80 | CDK1 (0.46) | CDK1ADORA2AADORA1YTHDC1CDK5 | |
| SCHEMBL7289687 | 0.77 | CDK1 (0.51) | CDK1ADORA2AADORA1YTHDC1CDK5 | |
| SCHEMBL12359908 | 0.74 | PKM (0.41) | CDK1ADORA2AADORA1YTHDC1CCNB1 | |
| SCHEMBL12359911 | 0.74 | KDM4E (0.41) | CDK1ADORA2AADORA1YTHDC1CDK5 | |
| SCHEMBL24654972 | 0.74 | CDK1 (0.41) | CDK1ADORA2AADORA1YTHDC1CDK5 | |
| SCHEMBL14441699 | 0.74 | CDK1 (0.41) | CDK1ADORA2AADORA1YTHDC1CDK5 | |
| SCHEMBL18721931 | 0.72 | ADORA1 (0.60) | CDK1ADORA2AADORA1YTHDC1CDK5 | |
| SCHEMBL14131868 | 0.72 | CDK1 (0.64) | CDK1ADORA2AADORA1YTHDC1CDK5 | |
| SCHEMBL19464460 | 0.68 | CDK1 (0.49) | CDK1ADORA2AADORA1YTHDC1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | CDK1 1221/4885ADORA2A 4423/4885ADORA1 4786/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | CDK1 1221/4885ADORA2A 4423/4885ADORA1 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.